M
10b5-1 Plan
$ Value
$189K
Shares
6,394
Price
$30
Filed
Nov 18
Insider
Name
Davis John E
Title
Chief Commercial Officer
CIK
0001653206
Roles
Officer
Transaction Details
Transaction Date
2025-11-17
Code
M
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
205,236
Footnotes
The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025. | Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020.
Filing Info
Davis John E's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-03 | AORT | ▼ | $173K |
| 2026-03-02 | AORT | ▼ | $106K |
| 2026-03-02 | AORT | A | $0 |
| 2026-02-24 | AORT | ▼ | $74K |
| 2026-02-24 | AORT | A | $0 |
| 2026-02-23 | AORT | ▼ | $142K |
| 2025-12-15 | AORT | ▼ | $226K |
| 2025-11-17 | AORT | M | $189K |
| 2025-11-17 | AORT | ▼ | $289K |
| 2025-11-17 | AORT | M | $0 |
Other Insiders at AORT (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Horton Amy
VP, Chief Accounting Officer
|
— | $153K | 2026-03-03 |
|
Mackin James P
President & CEO
|
— | $2.5M | 2026-03-03 |
|
Berry Lance A
EVP, COO, CFO & Treasurer
|
— | $783K | 2026-03-03 |
|
Holloway Jean F
SVP, General Counsel
|
— | $744K | 2026-03-04 |
|
Davis John E
Chief Commercial Officer
|
— | $494K | 2026-03-03 |
|
Stanton Marshall S.
SVP, Clinical & MD Affair
|
— | $275K | 2026-03-03 |